Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...

More than a decade after coining “Treat Yo’ Self Day” in her role as Donna on “Parks & Recreation,” Retta is once again ...

Tandem Diabetes TNDM is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

DexCom Inc (DXCM) stock saw a decline, ending the day at $68.94 which represents a decrease of $-1.15 or -1.64% from the prior close of $70.09. The stock opened at $69.99 and touched a low of $68.59 ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) on September 13 and set a price target of ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

DexCom Inc (DXCM) stock saw a modest uptick, ending the day at $69.71 which represents a slight increase of $1.10 or 1.60% from the prior close of $68.61. The stock opened at $68.87 and touched a low ...

Shares of DexCom Inc. DXCM rallied 1.60% to $69.71 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.16% to 5,471.05 ...